Maria Bjorkqvist

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1701006/publications.pdf

Version: 2024-02-01

72 papers	4,804 citations	109321 35 h-index	95266 68 g-index
75 all docs	75 docs citations	75 times ranked	5360 citing authors

#	Article	IF	Citations
1	A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. Journal of Experimental Medicine, 2008, 205, 1869-1877.	8.5	559
2	Interleukin-6 Is Elevated in the Cerebrospinal Fluid of Suicide Attempters and Related to Symptom Severity. Biological Psychiatry, 2009, 66, 287-292.	1.3	436
3	Beyond the brain: widespread pathology in Huntington's disease. Lancet Neurology, The, 2009, 8, 765-774.	10.2	312
4	Orexin loss in Huntington's disease. Human Molecular Genetics, 2005, 14, 39-47.	2.9	246
5	Proteomic Profiling of Plasma in Huntington's Disease Reveals Neuroinflammatory Activation and Biomarker Candidates. Journal of Proteome Research, 2007, 6, 2833-2840.	3.7	212
6	Hsa-miR-34b is a plasma-stable microRNA that is elevated in pre-manifest Huntington's disease. Human Molecular Genetics, 2011, 20, 2225-2237.	2.9	183
7	Reduced orexin levels in the cerebrospinal fluid of suicidal patients with major depressive disorder. European Neuropsychopharmacology, 2007, 17, 573-579.	0.7	176
8	Hypothalamicâ€“endocrine aspects in Huntington's disease. European Journal of Neuroscience, 2006, 24, 961-967.	2.6	167
9	HTT-lowering reverses Huntingtonâ€™s disease immune dysfunction caused by NFÎºB pathway dysregulation. Brain, 2014, 137, 819-833.	7.6	147
10	The R6/2 transgenic mouse model of Huntington's disease develops diabetes due to deficient Î²-cell mass and exocytosis. Human Molecular Genetics, 2005, 14, 565-574.	2.9	129
11	Progressive alterations in the hypothalamic-pituitary-adrenal axis in the R6/2 transgenic mouse model of Huntington's disease. Human Molecular Genetics, 2006, 15, 1713-1721.	2.9	122
12	Increased metabolism in the R6/2 mouse model of Huntingtonâ€™s disease. Neurobiology of Disease, 2008, 29, 41-51.	4.4	114
13	Evaluation of a Previously Suggested Plasma Biomarker Panel to Identify Alzheimer's Disease. PLoS ONE, 2012, 7, e29868.	2.5	106
14	Neurohormonal regulation of histamine and pancreastatin secretion from isolated rat stomach ECL cells. Regulatory Peptides, 1997, 71, 73-86.	1.9	98
15	Abnormal peripheral chemokine profile in Huntingtonâ€™s disease. PLOS Currents, 2011, 3, RRN1231.	1.4	96
16	Testicular degeneration in Huntington disease. Neurobiology of Disease, 2007, 26, 512-520.	4.4	90
17	Gastrointestinal dysfunction contributes to weight loss in Huntington's disease mice. Neurobiology of Disease, 2011, 44, 1-8.	4.4	88
18	Ghrelin and Motilin Are Cosecreted from a Prominent Endocrine Cell Population in the Small Intestine. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3573-3581.	3.6	83

#	Article	IF	Citations
19	Increased thirst and drinking in Huntington's disease and the R6/2 mouse. Brain Research Bulletin, 2008, 76, 70-79.	3.0	82
20	Plasma melatonin is reduced in Huntington's disease. Movement Disorders, 2014, 29, 1511-1515.	3.9	81
21	Orexin and psychiatric symptoms in suicide attempters. Journal of Affective Disorders, 2007, 100, 259-263.	4.1	76
22	Bone Marrow Transplantation Confers Modest Benefits in Mouse Models of Huntington's Disease. Journal of Neuroscience, 2012, 32, 133-142.	3.6	71
23	CART Regulates Islet Hormone Secretion and Is Expressed in the Î²-Cells of Type 2 Diabetic Rats. Diabetes, 2006, 55, 305-311.	0.6	63
24	Reduction of GnRH and infertility in the R6/2 mouse model of Huntington's disease. European Journal of Neuroscience, 2005, 22, 1541-1546.	2.6	61
25	Increased orexin levels in the cerebrospinal fluid the first year after a suicide attempt. Journal of Affective Disorders, 2009, 113, 179-182.	4.1	61
26	Increased intestinal permeability and gut dysbiosis in the R6/2 mouse model of Huntingtonâ€™s disease. Scientific Reports, 2020, 10, 18270.	3.3	59
27	Characterisation of immune cell function in fragment and full-length Huntington's disease mouse models. Neurobiology of Disease, 2015, 73, 388-398.	4.4	50
28	Neurofilament light protein in CSF and blood is associated with neurodegeneration and disease severity in Huntingtonâ€™s disease R6/2 mice. Scientific Reports, 2017, 7, 14114.	3.3	49
29	Mutant huntingtin interacts with Â-tubulin and disrupts vesicular transport and insulin secretion. Human Molecular Genetics, 2009, 18, 3942-3954.	2.9	43
30	Perturbations in the p53/miR-34a/SIRT1 pathway in the R6/2 Huntington's disease model. Molecular and Cellular Neurosciences, 2018, 88, 118-129.	2.2	41
31	A Metabolic Study of Huntingtonâ€™s Disease. PLoS ONE, 2016, 11, e0146480.	2.5	41
32	A Critical Evaluation of Wet Biomarkers for Huntingtonâ€™s Disease: Current Status and Ways Forward. Journal of Huntington's Disease, 2018, 7, 109-135.	1.9	38
33	Pharmacological analysis of CCK2receptor antagonists using isolated rat stomach ECL cells. British Journal of Pharmacology, 1999, 127, 530-536.	5.4	37
34	Cell-specific Processing of Chromogranin A in Endocrine Cells of the Rat Stomach. Journal of Histochemistry and Cytochemistry, 2001, 49, 9-18.	2.5	37
35	Role of gastrin in the development of gastric mucosa, ECL cells and A-like cells in newborn and young rats. Regulatory Peptides, 2002, 108, 73-82.	1.9	36
36	Harnessing Immune Alterations in Neurodegenerative Diseases. Neuron, 2009, 64, 21-24.	8.1	36

#	Article	IF	Citations
37	No Diagnostic Value of Plasma Clusterin in Alzheimer's Disease. PLoS ONE, 2012, 7, e50237.	2.5	36
38	Increased numbers of motor activity peaks during light cycle are associated with reductions in adrenergic Î±2-receptor levels in a transgenic Huntington's disease rat model. Behavioural Brain Research, 2009, 205, 175-182.	2.2	35
39	Gastrin and the neuropeptide PACAP evoke secretion from rat stomach histamineâ€containing (ECL) cells by stimulating influx of Ca 2+ through different Ca 2+ channels. Journal of Physiology, 2001, 535, 663-677.	2.9	30
40	A Critical Evaluation of Inflammatory Markers in Huntington's Disease Plasma. Journal of Huntington's Disease, 2013, 2, 125-134.	1.9	25
41	Islet Î²-cell area and hormone expression are unaltered in Huntingtonâ€™s disease. Histochemistry and Cell Biology, 2008, 129, 623-629.	1.7	24
42	A 24-Hour Study of the Hypothalamo-Pituitary Axes in Huntingtonâ€™s Disease. PLoS ONE, 2015, 10, e0138848.	2.5	22
43	Brain pericyte activation occurs early in Huntington's disease. Experimental Neurology, 2018, 305, 139-150.	4.1	22
44	Dual Therapy with Liraglutide and Ghrelin Promotes Brain and Peripheral Energy Metabolism in the R6/2 Mouse Model of Huntingtonâ€™s Disease. Scientific Reports, 2018, 8, 8961.	3.3	20
45	Cocaineâ€•and amphetamineâ€regulated transcript is increased in Huntington disease. Movement Disorders, 2007, 22, 1952-1954.	3.9	18
46	White Adipose Tissue Browning in the R6/2 Mouse Model of Huntingtonâ€™s Disease. PLoS ONE, 2016, 11, e0159870.	2.5	18
47	Neuropeptide Y (<scp>NPY</scp>) in cerebrospinal fluid from patients with Huntington's Disease: increased <scp>NPY</scp> levels and differential degradation of the <scp>NPY</scp>_{1â€“30} fragment. Journal of Neurochemistry, 2016, 137, 820-837.	3.9	17
48	Ghrelin rescues skeletal muscle catabolic profile in the R6/2 mouse model of Huntingtonâ€™s disease. Scientific Reports, 2017, 7, 13896.	3.3	17
49	Immune markers for Huntingtonâ€™s disease?. Expert Review of Neurotherapeutics, 2008, 8, 1779-1781.	2.8	16
50	Skeletal Muscle Atrophy in R6/2 Mice â€“ Altered Circulating Skeletal Muscle Markers and Gene Expression Profile Changes. Journal of Huntington's Disease, 2014, 3, 13-24.	1.9	16
51	Somatostatin, misoprostol and galanin inhibit gastrin- and PACAP-stimulated secretion of histamine and pancreastatin from ECL cells by blocking specific Ca2+ channels. Regulatory Peptides, 2005, 130, 81-90.	1.9	15
52	Automated Behavioral Phenotyping Reveals Presymptomatic Alterations in a SCA3 Genetrap Mouse Model. Journal of Genetics and Genomics, 2012, 39, 287-299.	3.9	15
53	JAK/STAT Signalling in Huntingtonâ€™s Disease Immune Cells. PLOS Currents, 2013, 5, .	1.4	15
54	Leptin deficiency reverses high metabolic state and weight loss without affecting central pathology in the R6/2 mouse model of Huntington's disease. Neurobiology of Disease, 2019, 132, 104560.	4.4	14

#	Article	IF	Citations
55	Analysis of White Adipose Tissue Gene Expression Reveals CREB1 Pathway Altered in Huntingtonâ€™s Disease. Journal of Huntington's Disease, 2015, 4, 371-382.	1.9	11
56	Hypothalamic expression of huntingtin causes distinct metabolic changes in Huntington's disease mice. Molecular Metabolism, 2022, 57, 101439.	6.5	11
57	Characterization of Gastric Mucosa Biopsies Reveals Alterations in Huntington's Disease. PLOS Currents, 2015, 7, .	1.4	10
58	Gastrin-induced gene expression in oxyntic mucosa and ECL cells of rat stomach. Regulatory Peptides, 1999, 84, 29-35.	1.9	9
59	Effects of CCK2 Receptor Blockade on Growth Parameters in Gastrointestinal Tract and Pancreas in Rats. Basic and Clinical Pharmacology and Toxicology, 2001, 89, 208-213.	0.0	9
60	Flt3 ligand does not differentiate between Parkinsonian disorders. Movement Disorders, 2014, 29, 1319-1322.	3.9	9
61	Cocaine and amphetamine regulated transcript (CART) in suicide attempters. Psychiatry Research, 2008, 158, 117-122.	3.3	7
62	A porous silicon immunoassay platform for fluorometric determination of Î±-synuclein in human cerebrospinal fluid. Mikrochimica Acta, 2014, 181, 1143-1149.	5.0	7
63	Serum levels of a subset of cytokines show high interindividual variability and are not altered in rats transgenic for HuntingtonÂ's disease. PLOS Currents, 2010, 2, RRN1190.	1.4	7
64	Inflammatory markers in Huntington's disease plasmaâ€”A robust nanoLCâ€“MRM-MS assay development. EuPA Open Proteomics, 2014, 3, 68-75.	2.5	6
65	A hypothesis for insulin resistance in primary human adipocytes involving MRTF-A and suppression of PPARÎ³. Biochemical and Biophysical Research Communications, 2020, 533, 64-69.	2.1	5
66	Drug repositioning in Alzheimer rsquo s disease. Frontiers in Bioscience - Scholar, 2015, 7, 184-188.	2.1	5
67	Immunomodulation â€“ a diseaseâ€modifying avenue for treatment of Huntington's disease?. Journal of Neurochemistry, 2016, 137, 670-672.	3.9	2
68	Effects of excitotoxicity in the hypothalamus in transgenic mouse models of Huntington disease. Heliyon, 2021, 7, e07808.	3.2	2
69	Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimerâ€™s disease. BMC Neurology, 2015, 15, 8.	1.8	1
70	B31â€...Sirt1 expression, regulation and activity in R6/2 mice. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A20.1-A20.	1.9	1
71	A53â€...Effects of hypothalamic circuitries on pathology in the ventral striatum in mouse models of huntington disease. , 2018, , .		0
72	A54â€...The role of excitotoxicity for neuropathology in the lateral hypothalamus in mouse models of huntington disease. , 2018, , .		0